So Long and Thanks for all the Drugs
Scott Gottlieb prepares to leave the FDA after accomplishing much.
Stephanie Sutton | | Quick Read
You have probably all heard the news from the US: Scott Gottlieb has resigned from the role of FDA Commissioner (1). When he was first appointed, concerns were raised about his ties with the pharma industry, but Gottlieb will leave with his head held high. He has earned bipartisan praise, been highly active on drug pricing issues, helped speed up generic approvals, advocated for continuous processing and modern drug manufacturing methods, and been unafraid to call out abuse of any aspects of the system by drugmakers. And he has done all of this while still maintaining a good relationship with the industry. He’s also been active on other important healthcare topics; just a few weeks ago, he insinuated that certain states with lax vaccination rules may force the hands of regulators, given the shocking rise of measles outbreaks in the US (2).
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.